Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc (NASDAQ: ABEO) is a clinical-stage biopharmaceutical leader advancing gene therapies for rare genetic diseases. This dedicated news hub provides investors and researchers with essential updates on ABEO’s therapeutic developments, regulatory milestones, and scientific partnerships.
Discover timely press releases detailing progress in AAV-based therapies, CRISPR/Cas9 research, and pivotal clinical trials for conditions like epidermolysis bullosa. Our curated collection includes FDA correspondence updates, manufacturing quality certifications, and strategic collaboration announcements – all critical for evaluating the company’s trajectory.
Key content categories feature BLA submission statuses, Phase 3 trial results, and technology licensing agreements. Bookmark this page for streamlined access to verified updates about ABEO’s pipeline candidates and operational developments, presented with clarity for both professional analysts and engaged stakeholders.
Abeona Therapeutics (Nasdaq: ABEO) has announced new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). On July 31, 2024, the company's Compensation Committee approved restricted stock equity awards for two new non-executive employees. These awards total up to 4,500 restricted shares of Abeona common stock. The vesting schedule for these awards is as follows:
- One-third of the shares will vest yearly on each anniversary of the Grant Date
- Full vesting will occur on the third anniversary of the Grant Date
- Vesting is subject to continued employment with Abeona on the applicable dates
These equity awards are designed to serve as a material inducement for employment at Abeona Therapeutics.
Abeona Therapeutics (Nasdaq: ABEO) and Beacon Therapeutics have signed a non-exclusive agreement for Beacon to evaluate Abeona's AAV204 capsid for ophthalmology gene therapies. AAV204, part of Abeona's AIM™ capsid library, shows promising transduction levels in macular and optic nerve tissues. Beacon has a 12-month evaluation period with options for a worldwide license covering up to five gene targets. Abeona stands to receive upfront payments, milestone payments, and royalties on net sales of licensed products. Beacon will handle development and commercialization of the therapies, which address distinct targets from Abeona's current projects.
Abeona Therapeutics (Nasdaq: ABEO) will participate in the Stifel Virtual Cell Therapy Forum on July 9, 2024. The company's CEO, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will engage in a virtual fireside chat at 9:45 a.m. Eastern Time.
A live webcast of the discussion will be accessible on the Investors section of Abeona's website under the 'Events' tab. The webcast will also be archived for 30 days for later viewing.
Abeona Therapeutics (Nasdaq: ABEO) announced the issuance of new equity awards to recently hired non-executive employees.
The grants, sanctioned under Nasdaq Listing Rule 5635(c)(4), were approved by Abeona's Compensation Committee on May 31, 2024.
A total of 5,500 restricted shares of Abeona common stock were allocated across three new hires as an employment inducement.
The vesting schedule for these shares is set over three years, with one-third vesting on each anniversary of the grant date, contingent upon continuous employment with Abeona.
Abeona Therapeutics announced its senior management will be participating in the Jefferies Global Healthcare Conference on June 6, 2024. The event will feature a fireside chat at 11:30 a.m. Eastern Time and one-on-one investor meetings. A live webcast of the chat will be available on the company's investor section, remaining accessible for 30 days.
Abeona Therapeutics (Nasdaq: ABEO) reported financial results for Q1 2024 and recent corporate progress. A significant highlight is the recent $75 million underwritten securities offering, extending the cash runway into 2026.
In April 2024, the FDA issued a Complete Response Letter (CRL) for their BLA for prademagene zamikeracel (pz-cel) for RDEB, citing the need for additional CMC information. However, no deficiencies were noted in clinical efficacy or safety data. The resubmission of the BLA is expected in the second half of 2024.
Financially, Abeona reported a net loss of $31.6 million for Q1 2024, an increase from $9.1 million in Q1 2023. R&D expenses decreased slightly while G&A expenses increased compared to the same period last year. Cash and equivalents totaled $62.7 million as of March 31, 2024.
Abeona Therapeutics Inc. (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved restricted stock equity awards totaling up to 37,200 shares of common stock for ten new hires. One-third of the shares will vest yearly over three years, contingent on continued employment.
Abeona Therapeutics Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, expected to generate approximately $75 million in gross proceeds. The offering includes both new and existing investors, with the funds intended for the resubmission of its BLA, commercialization of its product candidate pz-cel, and general corporate purposes.
FAQ
What is the current stock price of Abeona Therapeut (ABEO)?
What is the market cap of Abeona Therapeut (ABEO)?
